<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Albuterol (salbutamol): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Albuterol (salbutamol): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Albuterol (salbutamol): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9396" href="/d/html/9396.html" rel="external">see "Albuterol (salbutamol): Drug information"</a> and <a class="drug drug_patient" data-topicid="12455" href="/d/html/12455.html" rel="external">see "Albuterol (salbutamol): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F130976"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ProAir Digihaler;</li>
<li>ProAir HFA [DSC];</li>
<li>ProAir RespiClick;</li>
<li>Proventil HFA;</li>
<li>Ventolin HFA</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865579"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Airomir;</li>
<li>APO-Salbutamol HFA;</li>
<li>DOM-Salbutamol;</li>
<li>PMS-Salbutamol;</li>
<li>TEVA-Salbutamol;</li>
<li>TEVA-Salbutamol HFA;</li>
<li>Ventolin;</li>
<li>Ventolin Diskus;</li>
<li>Ventolin HFA;</li>
<li>Ventolin PF [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056301"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Beta<sub>2</sub>-Adrenergic Agonist</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span>;</li>
<li>
<span class="list-set-name">Sympathomimetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462358"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="164d899f-979f-4050-a129-8a6a21b144a7">Bronchodilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchodilation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nebulization:</i> Oral inhalation: Usual reported dose: 1.25 to 2.5 mg/dose; typically administered every 6 to 8 hours, but may be administered more frequently if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11749685','lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11749685','lexi-content-ref-Eichenwald.1'])">Ref</a></span>). In a retrospective report, 16 very low birth weight (VLBW) neonates (mean GA: 26.1 ± 1.2 weeks; mean birthweight: 817 ± 211 g) received 1.25 mg/dose every 8 hours for &gt;2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19598281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19598281'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Metered-dose inhaler:</i> 90 mcg/actuation: Oral inhalation: 1 to 2 inhalations administered into the ventilator circuit was the most frequently reported dose in a survey of 68 neonatal intensive care units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11749685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11749685'])">Ref</a></span>); typically used every 6 to 8 hours; may use more frequently if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1','lexi-content-ref-9828734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1','lexi-content-ref-9828734'])">Ref</a></span>); up to 5 inhalations have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cda22604-bf62-4c29-b891-c4e684e5c1e9">Hyperkalemia; adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia; adjunct therapy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Albuterol is administered to shift potassium intracellularly and may be administered concomitantly with IV insulin and dextrose infusion for additive effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24139581','lexi-content-ref-32852924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24139581','lexi-content-ref-32852924'])">Ref</a></span>). Albuterol should not be used as the sole agent for treating moderate to severe hyperkalemia; use in combination with therapies to stabilize myocardium and eliminate potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24139581','lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24139581','lexi-content-ref-21181208'])">Ref</a></span>). Use caution in patients with preexisting cardiac disorders (eg, arrhythmias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); patients should be on a cardiac monitor during administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Nebulization: Oral inhalation: 0.4 mg (in 2 mL of NS) up to every 2 hours; dosing based on 2 randomized trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30839405','lexi-content-ref-12091845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30839405','lexi-content-ref-12091845'])">Ref</a></span>). In one trial 40 neonates (GA range: 25 to 32 weeks) with serum potassium concentration &gt;6 mEq/L within 72 hours of birth were randomized to receive nebulized albuterol once (n=20) or a glucose-insulin infusion (n=20). The second trial included premature neonates (mean GA: 25 ± 1 weeks; mean PNA: 5 ± 1 days) with a birthweight &lt;2 kg (mean birthweight: 736 ± 89 g) with serum potassium concentration ≥6 mEq/L who received nebulized albuterol (n=8) every 2 hours until potassium &lt;5 mEq/L (up to 12 doses) or placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12091845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12091845'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F131004"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Unless otherwise noted, dosing for the metered-dose inhaler (MDI) and dry powder inhaler (DPI) formulations is based on US products (90 mcg/actuation). A valved holding chamber or spacer is recommended for use with an MDI in patients with poor technique and is the recommended medication delivery system in all patients ≤5 years of age, with the addition of a mask for patients &lt;3 or 4 years of age or until proper technique is demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>). A DPI does not require use of a valved holding chamber.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> GINA guideline dosing is based on the 100 mcg/actuation salbutamol product (not available in the United States) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>). Use of oral albuterol formulations (eg, tablet, syrup) for management of acute asthma or long-term daily maintenance treatment is not recommended due to delayed onset of action and risk of adverse effects; scheduled daily inhaled albuterol use is not recommended for long-term maintenance treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>). Increasing use or regular use &gt;2 days/week for symptom control (except prevention of exercise-induced bronchospasm) indicates inadequate control and need for additional long-term control therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1','lexi-content-ref-NAEPP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1','lexi-content-ref-NAEPP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute symptom relief:</b></i>
<b>Note:</b> For use as an as-needed reliever therapy for acute symptoms outside of an exacerbation. In select patients ≥4 years of age, as needed beta-agonists should be used in combination with inhaled corticosteroids (ICS) by either administering as-needed albuterol immediately followed by ICS or using a combination ICS and formoterol inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17166990','lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17166990','lexi-content-ref-GINA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>MDI, DPI:</i> 90 mcg/actuation:<b> Note:</b> Young children and patients with severe symptoms may have reduced inspiratory flow which may reduce drug deposition in the lung from a DPI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15334507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15334507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Limited data available in ages &lt;4 years: Oral inhalation: 2 inhalations every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>); 1 inhalation every 4 hours may be sufficient in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nebulization</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children ≤4 years: Limited data available in ages &lt;2 years: Oral inhalation: 0.63 to 2.5 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children &gt;4 to &lt;12 years: Oral inhalation: 1.25 to 5 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral inhalation: Usual dose: 2.5 mg every 6 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Reported range: 1.25 to 5 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute exacerbation:</i> Note: </b>Use for progressively worsening asthma symptoms not responding to as-needed reliever therapy. Beta-agonists are often used in conjunction with systemic glucocorticoids in patients with acute exacerbations.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Home management: </i>Note:</b> Patients with severe symptoms or worsening symptoms despite initial care should seek immediate medical attention.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>MDI, DPI: </i>90 mcg/actuation: <b>Note: </b>Young children and patients with severe symptoms may have reduced inspiratory flow which may reduce drug deposition in the lung from a DPI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15334507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15334507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Infants: Oral inhalation: 2 inhalations every 20 minutes as needed for 2 to 3 doses; patients with more severe symptoms may require up to 4 inhalations/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>); if initial response is good, lengthen dosing frequency and administer 2 to 4 inhalations every 3 to 4 hours for 24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Children and Adolescents: Oral inhalation: 2 to 4 inhalations every 20 minutes as needed for 2 to 3 doses; patients with more severe symptoms may require up to 6 inhalations/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-BTS.1','lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-BTS.1','lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>); if initial response is good, lengthen dosing frequency and administer 2 to 6 inhalations every 3 to 4 hours for 24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Nebulization:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children ≤4 years: Limited data available in ages &lt;2 years: Oral inhalation: Usual dose: 1.25 to 2.5 mg every 20 minutes for 3 doses if needed; if initial response is good, lengthen dosing frequency and administer 1.25 to 2.5 mg every 3 to 4 hours for 24 to 48 hours; reported range: 0.63 to 2.5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Children &gt;4 to &lt;12 years: Oral inhalation: Usual dose: 2.5 to 5 mg every 20 minutes for 3 doses if needed; if initial response is good, lengthen dosing frequency and administer 2.5 to 5 mg every 3 to 4 hours for 24 to 48 hours; reported range: 1.25 to 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1','lexi-content-ref-22702533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1','lexi-content-ref-22702533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: Oral inhalation: Usual dose: 2.5 mg every 20 minutes for the first hour if needed; if initial response is good, lengthen dosing frequency and administer 2.5 mg every 3 to 4 hours for 24 to 48 hours; reported range: 1.25 to 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Primary care/acute care management:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>MDI, DPI:</i> 90 mcg/actuation: <b>Note: </b>Young children and patients with severe symptoms may have reduced inspiratory flow which may reduce drug deposition in the lung from a DPI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15334507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15334507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children &lt;12 years: Limited data available in ages &lt;4 years: Oral inhalation: 4 to 8 inhalations every 20 minutes for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-NAEPP.1'])">Ref</a></span>); for patients ≥6 years of age, some experts recommend doses up to 10 inhalations/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-BTS.1','lexi-content-ref-GINA.1','lexi-content-ref-22702533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-BTS.1','lexi-content-ref-GINA.1','lexi-content-ref-22702533'])">Ref</a></span>). Weight-band dosing may also be used by some centers; doses based on patient weight as follows: 5 to &lt;10 kg: 4 inhalations; 10 to &lt;20 kg: 6 inhalations; ≥20 kg: 8 inhalations; doses are administered every 20 minutes for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31676529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31676529'])">Ref</a></span>). After the initial hour, dose may vary from 4 to 10 inhalations every 1 to 4 hours based on patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: Oral inhalation: 4 to 8 inhalations every 20 minutes for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-NAEPP.1'])">Ref</a></span>); some experts recommend doses up to 10 inhalations/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-BTS.1','lexi-content-ref-GINA.1','lexi-content-ref-22702533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-BTS.1','lexi-content-ref-GINA.1','lexi-content-ref-22702533'])">Ref</a></span>). After the initial hour, dose may vary from 4 to 10 inhalations every 1 to 4 hours based on patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Nebulization:</i>
<b>Note:</b> Nebulization is preferred for patients who are unable to effectively use an MDI or DPI due to age, agitation, or severity of the exacerbation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent: Infants, Children, and Adolescents: Limited data available in ages &lt;2 years: Oral inhalation: 0.15 mg/<b>kg</b>/dose (minimum dose: 2.5 mg/dose; maximum dose: 5 mg/dose) every 20 minutes for 3 doses then 0.15 to 0.3 mg/<b>kg</b>/dose not to exceed 10 mg/dose every 1 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>). <b>Note:</b> For severe exacerbations, addition of ipratropium may be considered if poor response to initial aggressive short-acting beta<sub>2</sub>-agonist (SABA) therapy in an acute care setting (ie, emergency department). Ipratropium has not been shown to provide further benefit (eg, after first 24 hours) once the patient is hospitalized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Continuous nebulization: Dosing regimens variable; optimal dosage not established; consult institutional-specific protocols.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants and Children &lt;12 years: Initial: 0.5 mg/<b>kg</b>/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>); in patients with severe exacerbations doses as high as 1 mg/<b>kg</b>/hour may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23798903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23798903'])">Ref</a></span>). Weight-band dosing has also been reported; doses based on patient weight have been used as follows: 5 to &lt;10 kg: 5 to 7.5 mg/hour; 10 to &lt;20 kg: 10 mg/hour; ≥20 kg: 15 to 20 mg/hour. Adjust dose as needed based on patient response; maximum dose: 20 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23364383','lexi-content-ref-31676529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23364383','lexi-content-ref-31676529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥12 years and Adolescents: 10 to 15 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>); higher doses of up to 20 mg/hour have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23364383','lexi-content-ref-31676529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23364383','lexi-content-ref-31676529'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65751cc1-32f5-4d3e-9bf8-c56fb8c8a8cb">Bronchospasm, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchospasm, acute: Note: </b>Use for acute bronchospasm outside of asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prevention: </i></b>Limited data available; optimal dose not established. <b>Note: </b>Administer prior to anticipated exposure to triggers (eg, bronchospastic inhaled therapies), airway clearance techniques (eg, cystic fibrosis) or in high-risk patients (eg, history of asthma, wheezing, recent upper respiratory tract infection) prior to procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8058420','lexi-content-ref-16421365','lexi-content-ref-19219329','lexi-content-ref-28291127','lexi-content-ref-11574353','lexi-content-ref-19694973','lexi-content-ref-31009034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8058420','lexi-content-ref-16421365','lexi-content-ref-19219329','lexi-content-ref-28291127','lexi-content-ref-11574353','lexi-content-ref-19694973','lexi-content-ref-31009034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>MDI, DPI:</i> 90 mcg/actuation: Oral inhalation: 2 to 4 inhalations administered 10 to 30 minutes prior to trigger exposure, airway clearance techniques, or procedure.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Nebulization: </i>Oral inhalation: 2.5 mg administered 10 to 30 minutes prior to trigger exposure, airway clearance techniques, or procedure; some patients may require doses up to 5 mg based on history and individual risk factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment</i>:</b> Limited data available: <b>Note: </b>Albuterol has been used in the treatment of bronchospasm/wheezing due to conditions such as viral illness, contrast reactions, or as adjunct to epinephrine in the treatment of anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-ACR.1','lexi-content-ref-22211074','lexi-content-ref-8118539','lexi-content-ref-1513726','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-ACR.1','lexi-content-ref-22211074','lexi-content-ref-8118539','lexi-content-ref-1513726','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>MDI, DPI:</i> 90 mcg/actuation: Oral inhalation: 2 inhalations; repeat as needed; frequency may vary and range from every 4 to 6 hours as needed up to every 20 minutes for 3 doses based on patient response; patients with history of asthma may require higher doses (ie, 5 to 10 inhalations every 20 minutes) in some situations (eg, when used as adjunct therapy in anaphylaxis).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Nebulization:</i> Oral inhalation: 2.5 to 5 mg; repeat as needed based on clinical condition, symptoms, and response; may give as frequently as every 20 minutes for up to 3 doses or may administer continuously if needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f9822de-f4f8-46a5-9c0e-060c78aa226d">Exercise-induced bronchoconstriction, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise-induced bronchoconstriction, prevention: Note:</b> Tolerance to the protective effects of albuterol against exercise-induced bronchospasm may develop with regular daily use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-GINA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MDI, DPI:</i> 90 mcg/actuation:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;4 years: Limited data available: Oral inhalation: 1 to 2 inhalations 5 to 20 minutes before exercising (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-NAEPP.1'])">Ref</a></span>). <b>Note: </b>Pretreatment in patients &lt;4 years of age should only be used when a specific triggering activity can be clearly identified.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: Oral inhalation: 2 inhalations 5 to 20 minutes before exercising (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-NAEPP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-NAEPP.1','lexi-content-ref-manu.1'])">Ref</a></span>); doses up to 4 inhalations have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21682173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21682173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian formulation: </i>DPI: 200 mcg/inhalation: Children ≥4 years and Adolescents: Oral inhalation: 1 inhalation 15 minutes before exercise.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc1818a0-0f66-4545-a67b-d6b92f0fe2c5">Hyperkalemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia (adjunct therapy):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Albuterol is administered to shift potassium intracellularly and may be administered concomitantly with IV insulin and dextrose infusion for additive effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24139581','lexi-content-ref-32852924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24139581','lexi-content-ref-32852924'])">Ref</a></span>). Albuterol should not be used as the sole agent for treating moderate to severe hyperkalemia; use in combination with therapies to stabilize myocardium and eliminate potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24139581','lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24139581','lexi-content-ref-21181208'])">Ref</a></span>). Use caution in patients with preexisting cardiac disorders (eg, arrhythmias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); patients should be on a cardiac monitor during administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-21920871','lexi-content-ref-8129434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-21920871','lexi-content-ref-8129434'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;25 kg: Nebulization: Oral inhalation: 2.5 mg nebulized over 10 minutes; dose may be repeated as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">25 to 50 kg: Nebulization: Oral inhalation: 5 mg nebulized over 10 minutes; dose may be repeated as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;50 kg: Nebulization: Oral inhalation: 10 mg nebulized over 10 minutes; dose may be repeated as needed. <b>Note: </b>Doses as high as 20 mg have been suggested for use in adults and may be utilized for larger children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9697678','lexi-content-ref-18936701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9697678','lexi-content-ref-18936701'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9de57b0e-a779-470a-861f-9579adba3901">Bronchospasm, patients unable to use or tolerate inhaled therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchospasm (long-term prevention), patients unable to use or tolerate inhaled therapy: Note: </b>Oral formulations of albuterol (eg, tablet, syrup) are not recommended; use is very rare because they are less effective than inhaled forms and more likely to cause adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23537669','lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1','lexi-content-ref-11399724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23537669','lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1','lexi-content-ref-11399724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate-release formulation (syrup, tablets)</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 6 years: Oral: Initial: 0.1 mg/<b>kg</b>/dose (maximum dose: 2 mg/dose) 3 times daily; if desired response not achieved, gradually increase dose to 0.2 mg/<b>kg</b>/dose (maximum dose: 4 mg/dose) 3 times daily; maximum daily dose: 12 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;6 and Adolescents ≤14 years: Oral: Initial: 2 mg 3 to 4 times daily; if desired response not achieved, gradually increase dose; maximum daily dose: 24 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;14 years: Oral: Initial: 2 to 4 mg 3 to 4 times daily; if desired response not achieved, gradually increase dose; maximum daily dose: 32 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-release formulation (tablets)</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 12 years: Oral: Initial: 4 mg every 12 hours; if control not achieved may gradually increase dose; maximum daily dose: 24 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: Initial: 4 to 8 mg every 12 hours; if control not achieved may gradually increase dose; maximum daily dose: 32 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51063772"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution when using high doses in patients with renal impairment. No dosage adjustment required, including patients on hemodialysis, peritoneal dialysis, or CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51063773"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F130981"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9396" href="/d/html/9396.html" rel="external">see "Albuterol (salbutamol): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Unless otherwise noted, dosing for the metered-dose inhaler (MDI) and dry powder inhaler (DPI) formulations is based on US products (90 mcg/actuation). A valved holding chamber (spacer) is recommended for use with an MDI. A DPI does not require use of a valved holding chamber.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute exacerbation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild to moderate exacerbations (initial home management)</i>: <b>Note:</b> Patients with worsening symptoms despite initial care should seek immediate medical attention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 2 to 4 inhalations every 20 minutes for 3 doses; if good response, can lengthen interval to every 3 to 4 hours as needed; if incomplete response, can lengthen interval to every 1 to 3 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Nebulization solution: <b>Oral inhalation:</b> 2.5 mg every 20 minutes for 3 doses; if good response, can lengthen interval to every 3 to 4 hours as needed; if incomplete response, can lengthen interval to every 1 to 3 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate to severe exacerbations (management in primary or acute care settings)</i>: <b>Note:</b> For moderate to severe exacerbations, albuterol is used in combination with an inhaled short-acting muscarinic antagonist. Nebulized therapy may be preferred in patients who have more severe symptoms or who cannot effectively use an inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 4 to 10 inhalations every 20 minutes for 3 doses, then taper as tolerated (eg, to 2 to 4 inhalations every 1 to 4 hours as needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>). High doses are typically administered in a monitored setting.</p>
<p style="text-indent:-2em;margin-left:8em;">Nebulization solution: <b>Oral inhalation:</b> 2.5 to 5 mg every 20 minutes for 3 doses, then taper as tolerated (eg, to 2.5 to 5 mg every 1 to 4 hours as needed). For critically ill patients, 10 to 15 mg may be administered by continuous nebulization over 1 hour via special apparatus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">IV continuous infusion [Canadian product]: <b>Note: </b>Reserve intravenous beta-agonists for those patients in whom inhaled therapy cannot be used reliably (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-BTS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-BTS.1'])">Ref</a></span>). Initial: 5 mcg/minute; may increase up to 10 to 20 mcg/minute at 15- to 30-minute intervals, if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent symptom relief (alternative agent): </b>
<b>Note: </b>Use in combination with an inhaled corticosteroid (preferred; may also be used alone) on an as-needed basis (reliever therapy) rather than regularly scheduled. For maintenance therapy, additional maintenance treatments should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulized therapy may be preferable for patients who have more severe symptoms or who cannot effectively use an inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 2 inhalations every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1'])">Ref</a></span>); some experts recommend up to 4 inhalations every 4 to 6 hours for moderate to severe symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Peters.1','lexi-content-ref-Wenzel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Peters.1','lexi-content-ref-Wenzel.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): <b>Oral inhalation:</b> 1 inhalation every 4 to 6 hours as needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Nebulization solution: <b>Oral inhalation:</b> 2.5 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lemanske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lemanske.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance therapy (alternative agent) (adjunctive therapy): </b>
<b>Note: </b>Oral formulations of albuterol (eg, tablet, syrup) are less effective than inhaled forms for bronchoconstriction and more likely to cause adrenergic adverse effects. For maintenance therapy, additional maintenance treatments (eg, inhaled corticosteroids) are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release</i> (syrup, tablets): <b>Oral:</b>
<b>Initial: </b>2 to 4 mg three to four times daily; if desired response not achieved, may gradually increase dose. Maximum daily dose: 32 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release</i> (tablets): <b>Oral:</b>
<b>Initial: </b>4 to 8 mg every 12 hours; if desired response not achieved, may gradually increase dose. In patients with low body weight, may consider an initial dose of 4 mg every 12 hours. Maximum daily dose: 32 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Exercise-induced bronchoconstriction (prevention):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 2 inhalations 5 to 20 minutes prior to exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23634861','lexi-content-ref-24089311','lexi-content-ref-OByrne.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23634861','lexi-content-ref-24089311','lexi-content-ref-OByrne.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): <b>Oral inhalation: </b>1 inhalation 15 minutes prior to exercise.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2d8b107-f512-4c36-8b8c-abb9dcfa5dda">Bronchospasm due to anaphylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchospasm (moderate to severe) due to anaphylaxis (adjunct to epinephrine): Note:</b> Administer epinephrine first when treating anaphylaxis; administer albuterol for residual respiratory symptoms not responding to epinephrine. Do <b>not</b> use albuterol for initial or sole treatment of anaphylaxis because albuterol does <b>not</b> prevent or relieve upper airway edema, hypotension, or shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-21377030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 2 to 3 inhalations as needed for symptom relief (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grammer.1','lexi-content-ref-Kang.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grammer.1','lexi-content-ref-Kang.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: <b>Oral inhalation: </b>2.5 to 5 mg; repeat as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-Campbell.1','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-Campbell.1','lexi-content-ref-21377030'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d52d5bc2-9161-4b32-97a1-49c0d38ae6b0">Chronic obstructive pulmonary disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute exacerbation:</b>
<b>Note:</b> Although similar efficacy exists among formulations, some experts prefer nebulized therapy during severe chronic obstructive pulmonary disease exacerbations. May be combined with an inhaled short-acting muscarinic antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 1 to 2 inhalations every 1 hour for 2 to 3 doses, then every 2 to 4 hours, as needed; for patients requiring emergency department or hospital-based care, may increase to 4 inhalations every 1 hour for 2 to 3 doses. For patients requiring mechanical ventilation, up to 8 inhalations may be used, if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization solution: <b>Oral inhalation:</b> 2.5 mg every 1 hour for 2 to 3 doses, then every 2 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent symptom relief</b>
<b>: Note:</b> Use for intermittent symptoms on an as-needed basis rather than regularly scheduled maintenance therapy. Typically used in combination with inhaled short-acting muscarinic antagonist; combination therapy provides greater improvement in FEV<sub>1</sub> and symptoms over monotherapy with a short-acting beta-2 agonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): <b>Oral inhalation:</b> 2 inhalations every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24364481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24364481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Canadian formulation: Ventolin Diskus [Canadian product]: Dry powder inhaler (200 mcg/inhalation): <b>Oral inhalation:</b> 1 inhalation every 4 to 6 hours as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization solution: <b>Oral inhalation: </b>2.5 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16002915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16002915'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc1818a0-0f66-4545-a67b-d6b92f0fe2c5">Hyperkalemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia (alternative agent) (adjunct) (off-label use):</b>
<b>Note:</b> May use after administration of standard therapies (calcium, insulin with dextrose, and potassium removal therapy) for those with continued symptoms or serious ECG manifestations or in patients for whom dialysis is not appropriate or feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral inhalation:</b> Nebulization solution: 10 to 20 mg via nebulization over 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2919849','lexi-content-ref-2266671','lexi-content-ref-9170015','lexi-content-ref-17897250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2919849','lexi-content-ref-2266671','lexi-content-ref-9170015','lexi-content-ref-17897250'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992011"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Oral inhalation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary (relatively low systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>IV continuous infusion [Canadian product]:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &gt;30 mL/min/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/min/1.73 m<sup>2</sup>: A substantial amount is eliminated in the urine (~65%), and albuterol may accumulate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969785'])">Ref</a></span>). No initial dosage adjustment necessary but use with caution and monitor for adverse effects. Where feasible, switch to inhaled formulations. Reduced doses may be necessary if used for more than 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>): Dose as for eGFR &lt;30 mL/min/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): Dose as for eGFR &lt;30 mL/min/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Dose as for eGFR &lt;30 mL/min/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Dose as for eGFR &lt;30 mL/min/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989258"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56355748"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Short-actingbeta-2 agonists (SABAs), such as albuterol, may cause mild <b>tachycardia</b>, <b>cardiac arrhythmias</b> (less common), QTc interval changes, and more severe cases of cardiac ischemia, heart failure, and <b>cardiomyopathy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12464943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12464943'])">Ref</a></span>). Swallowing-induced atrial tachyarrhythmia (SIAT) (<b>atrial tachycardia</b>) has rarely been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20552622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20552622'])">Ref</a></span>). <b>Supraventricular tachycardia</b> has been reported in a neonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25727842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25727842'])">Ref</a></span>). In pediatric patients receiving continuous albuterol, elevated troponin-T levels have been reported, the significance of which is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24599614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24599614'])">Ref</a></span>). Stress-induced cardiomyopathy (takotsubo cardiomyopathy) has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17662398','lexi-content-ref-27793870','lexi-content-ref-24855502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17662398','lexi-content-ref-27793870','lexi-content-ref-24855502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may be related to the pharmacologic action; beta-2 agonist effects on the heart as well as loss of beta-2 agonist selectivity at higher doses (ie, beta-1 agonist effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16060696','lexi-content-ref-20689475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16060696','lexi-content-ref-20689475'])">Ref</a></span>). Cardiac toxicity may occur in the setting of hypoxemia, secondary to vasodilation and possible pulmonary shunting, resulting in hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413357'])">Ref</a></span>). SIAT may be linked to triggering of adrenergic reflexes in the esophagus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20552622']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20552622'])">Ref</a></span>). Stress-induced cardiomyopathy may be due to catecholamine-induced reduction in blood flow, resulting in obstruction and secondary ischemia of the left ventricle and anterior wall (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24855502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24855502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; tachycardia may occur within 15 minutes after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19371312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19371312'])">Ref</a></span>). Cardiomyopathy may occur within days of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24855502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24855502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Overuse (dose and frequency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20689475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20689475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other sympathomimetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25727842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25727842'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease or predisposition to cardiovascular effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16060696','lexi-content-ref-27400984','lexi-content-ref-25727842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16060696','lexi-content-ref-27400984','lexi-content-ref-25727842'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Albuterol may cause CNS effects, including (but not limited to) <b>excitement</b>, <b>nervousness</b>,<b> tremor</b>, <b>anxiety</b>, <b>hyperactive behavior</b>, and <b>insomnia</b>. Excitement, nervousness, and insomnia may occur more frequently in younger pediatric patients (2 to 6 years) versus older pediatric patients and adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11861242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11861242'])">Ref</a></span>). There are also isolated case reports of <b>psychosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8748438','lexi-content-ref-2790100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8748438','lexi-content-ref-2790100'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Mechanism: Dose-related; related to the pharmacologic effect (ie, adrenergic CNS stimulation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berkovitch.1','lexi-content-ref-709492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berkovitch.1','lexi-content-ref-709492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Rapid; psychosis occurred within 2 days of overuse in one case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8748438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8748438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Overuse (dose and frequency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24509059','lexi-content-ref-2790100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24509059','lexi-content-ref-2790100'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Paradoxical bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Albuterol may cause <b>paradoxical bronchospasm</b> with an incidence in the literature ~4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30053954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30053954'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Mechanism: Non–dose-related; may be related to a hypersensitivity reaction or irritation to excipients in albuterol inhalers triggering airway hyperresponsiveness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30297688','lexi-content-ref-16174783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30297688','lexi-content-ref-16174783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Varied; occurred within 30 minutes in one case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174783'])">Ref</a></span>); has also occurred after months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30297688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30297688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dosage form (metered-dose inhaler and nebulizer solution) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174783'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Benzalkonium chloride (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377880','lexi-content-ref-30282664','lexi-content-ref-32165556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377880','lexi-content-ref-30282664','lexi-content-ref-32165556'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Edetate disodium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10725956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10725956'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F130942"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence of adverse effects is dependent upon age of patient, dose, and route of administration.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Excitement (children and adolescents: 2% to 20%), nervousness (4% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (5% to 38%; frequency increases with age)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (8% to 15%; exacerbation of underlying pulmonary disease), exacerbation of asthma (11% to 13%), pharyngitis (14%), rhinitis (5% to 16%), upper respiratory tract infection (5% to 21%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain (&lt;3%), edema (&lt;3%), extrasystoles (&lt;3%), flushing, hypertension (1% to 3%), palpitations, tachycardia (1% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 1</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption>
<b>Albuterol: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Albuterol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Albuterol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral syrup</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children, adolescents, and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral syrup</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">HFA inhalation aerosol</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">193</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">186</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">CFC 11/12 propelled inhaler</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">186</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">186</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (&lt;3%), pallor (children: 1%), skin rash (&lt;3%), urticaria (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (&lt;3%), increased serum glucose (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (children: 1%), diarrhea (&lt;3%), dyspepsia (1% to 2%), eructation (&lt;3%), flatulence (&lt;3%), gastroenteritis (3%), glossitis (&lt;3%), increased appetite (children and adolescents: 3%), nausea (2% to 10%), unpleasant taste (inhalation site: 4%), viral gastroenteritis (1% to 3%), vomiting (3% to 7%), xerostomia (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition, urinary tract infection (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (7%), decreased hemoglobin (7%), decreased white blood cell count (4%), lymphadenopathy (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (5%), increased serum aspartate aminotransferase (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cold symptoms (3%), infection (&lt;3%; skin/appendage: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site reaction (HFA inhaler: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (&lt;3%), ataxia (&lt;3%), depression (&lt;3%), dizziness (&lt;7%), drowsiness (&lt;3%), emotional lability (1%), fatigue (1%), headache (3% to 7%), hyperactive behavior (children and adolescents: 2%), insomnia (1% to 3%), malaise (2%), migraine (≤2%), pain (2%), restlessness, rigors (&lt;3%), shakiness (children and adolescents: 9%), vertigo, voice disorder (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2% to 4%), hyperkinetic muscle activity (≤4%), lower limb cramp (&lt;3%), muscle cramps (1% to 7%; frequency increases with age), musculoskeletal pain (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (children: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ear disease (&lt;3%), otalgia (&lt;3%), otitis media (≤4%), tinnitus (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≥2%), cough (≥3%), dyspnea (&lt;3%), epistaxis (children and adolescents: 1%), flu-like symptoms (3%), increased bronchial secretions (2%), laryngitis (&lt;3%), nasal congestion (1%), nasopharyngitis (≥5%; children: 2%), oropharyngeal edema (&lt;3%), oropharyngeal pain (≥5%; children: 2%), pulmonary disease (&lt;3%), respiratory system disorder (6%), sinus headache (1%), sinusitis (≥5%), throat irritation (10%), upper respiratory tract inflammation (5%), viral upper respiratory tract infection (7%), wheezing (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (&lt;3%), fever (≥5% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Depression of ST segment on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Epigastric pain, stomach pain (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Irritability, sleep disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, muscle spasm (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Mydriasis (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, atrial fibrillation, atrial tachycardia (Tandeter 2010), cardiac arrhythmia (Sears 2002), cardiomyopathy (takotsubo cardiomyopathy) (Khwaji 2016), hypotension, peripheral vasodilation, supraventricular tachycardia (Say 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Maggini 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Exacerbation of diabetes mellitus, hyperglycemia, hypokalemia (Udezue 1995), ketoacidosis, lactic acidosis, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, gag reflex, tongue ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychosis (Martin 1995; Whitehouse 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hoarseness, oropharyngeal irritation, paradoxical bronchospasm (Schissler 2018)</p></div>
<div class="block coi drugH1Div" id="F130958"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to albuterol or any component of the formulation; severe hypersensitivity to milk proteins (dry powder inhalers).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Ventolin: Hypersensitivity to albuterol or any component of the formulation; tachyarrhythmias; tocolytic use in patients at risk of premature labor or threatened abortion.</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation: Hypersensitivity to albuterol or any component of the formulation; tocolytic use in patients at risk of premature labor or threatened abortion.</p></div>
<div class="block war drugH1Div" id="F130939"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, heart failure). In a scientific statement from the American Heart Association, albuterol has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate to major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; beta-2 agonists may increase serum glucose and aggravate preexisting diabetes and ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with hypokalemia; beta-2 agonists may decrease serum potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Oral inhalation: Use spacer for children &lt;5 years of age and consider adding a face mask for infants and children &lt;4 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Dry powder inhalers may contain lactose; hypersensitivity reactions (eg, anaphylaxis, angioedema, pruritus, and rash) have been reported in patients with milk protein allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.</p></div>
<div class="block prod-avail drugH1Div" id="F57011041"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Albuterol ER tablets have been discontinued in the United States for &gt;1 year.</p></div>
<div class="block dosfc drugH1Div" id="F20995164"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">In the United States, the metered-dose inhaler (MDI) and dry powder inhaler (DPI) formulations provide 90 mcg/actuation (from the mouthpiece). In Canada, the MDI products are labeled as providing 100 mcg/actuation (per the valve depression [ie, from the valve]) and the DPI, Ventolin Diskus [Canadian product], provides 200 mcg/actuation.</p>
<p style="text-indent:-2em;margin-left:2em;">ProAir Digihaler 0.65 g inhaler, ProAir HFA 8.5 g canisters, ProAir RespiClick 0.65 g inhaler, Proventil HFA 6.7 g canisters, and Ventolin HFA 18 g canisters contain 200 inhalations. Ventolin HFA 8 g canisters contain 60 inhalations. The ProAir Digihaler is a digital inhaler which detects, records, and stores inhaler events, including peak inspiratory flow rate, and transmits data to a mobile application for inhaler use information.</p></div>
<div class="block foc drugH1Div" id="F130951"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ProAir Digihaler: 108 (90 Base) MCG/ACT (1 ea) [contains lactose monohydrate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ProAir RespiClick: 90 mcg/actuation (1 ea) [contains milk protein]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ProAir HFA: 90 mcg/actuation (8.5 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proventil HFA: 90 mcg/actuation (6.7 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proventil HFA: 90 mcg/actuation (6.7 g) [cfc free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin HFA: 90 mcg/actuation (8 g, 18 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 90 mcg/actuation (6.7 g, 8.5 g, 18 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (20 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/5 mL (120 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg [DSC], 8 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F130935"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F130960"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (ProAir Digihaler Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">108 (90 Base) mcg/ACT (per each): $108.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (ProAir RespiClick Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">108 (90 Base) mcg/ACT (per each): $81.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Albuterol Sulfate HFA Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">108 (90 Base) mcg/ACT (per gram): $1.61 - $13.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Proventil HFA Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">108 (90 Base) mcg/ACT (per gram): $14.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Ventolin HFA Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">108 (90 Base) mcg/ACT (per gram): $3.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Albuterol Sulfate Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.63 mg/3 mL (per mL): $0.28 - $0.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 mg/3 mL (per mL): $0.28 - $0.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">(2.5 MG/3ML) 0.083% (per mL): $0.27 - $0.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Albuterol Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/5 mL (per mL): $0.07 - $0.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Albuterol Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $5.87 - $5.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $5.87 - $5.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865580"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin Diskus: 200 mcg/actuation (1 ea) [contains lactose, milk protein]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Inhalation, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/actuation (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Inhalation, as sulfate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Airomir: 100 mcg/actuation (6.7 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin HFA: 100 mcg/actuation (17 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/actuation (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin: 0.5% [2.5 mg/0.5 mL] (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin PF: 0.1% ([DSC]); 0.2% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/mL (2.5 mL); 1 mg/mL (2.5 mL); 2 mg/mL (2.5 mL); 0.1% (2.5 mL); 0.2% (2.5 mL); 0.5% [2.5 mg/0.5 mL] (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin: 1 mg/mL (5 mL)</p></div>
<div class="block admp drugH1Div" id="F52612190"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral inhalation: In infants and children &lt;4 years of age, a face mask with either the metered-dose inhaler or nebulizer is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Metered-dose inhaler: Shake well before use; prime the inhaler prior to first use and whenever it has not been used for &gt;2 weeks or when it has been dropped by releasing 3 to 4 test sprays into the air away from the face. Airomir [Canadian product] labeling recommends releasing a minimum of 4 test sprays when priming. A valved holding chamber or spacer is recommended for use with an MDI in patients with poor technique and is the recommended medication delivery system in all patients ≤5 years of age, with the addition of a mask for patients &lt;3 or 4 years of age or until proper technique is demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>). Remove cap from mouthpiece and shake inhaler. Exhale fully prior to bringing inhaler to mouth. Place inhaler or valved holding chamber mouthpiece in mouth, close lips around mouthpiece, and inhale slowly and deeply while pressing down on the canister with your finger. Remove device and hold breath for as long as possible, up to 10 seconds. Breath out slowly. If prescribed dose is more than 1 inhalation, wait 1 minute between each inhalation and shake inhaler prior to each inhalation. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use. Discard inhaler when the dose indicator window displays "0".</p>
<p style="text-indent:-2em;margin-left:4em;">Dry powder inhaler:</p>
<p style="text-indent:-2em;margin-left:6em;">ProAir Digihaler, ProAir RespiClick: Inhaler device is breath-actuated; does not require priming. Hold the inhaler upright and open cap. When cap is opened and click is heard, the dose is activated; do not open until ready for dose. Before inhaling the dose, breathe out fully; do not exhale into the mouthpiece. Place inhaler in mouth, close lips around mouthpiece, and inhale quickly and deeply. Hold breath for about 10 seconds or for as long as comfortable and exhale slowly. If additional inhalations are needed for a full dose, close cap and repeat the process used for the first inhalation. Do not use with spacer or volume holding chamber. Keep inhaler clean and dry by wiping with dry cloth or tissue as needed; do not wash or put any part of inhaler in water. The dose indicator tells how many doses are left. When the number 20 appears in red, only a few doses remain, and the pharmacy should be contacted for a refill. Discard inhaler 13 months after removal from foil pouch or when the dose counter reads "0" (whichever comes first).</p>
<p style="text-indent:-2em;margin-left:6em;">Ventolin Diskus [Canadian product]: For oral inhalation route only. After opening the Diskus, hold in a level, horizontal position and activate by sliding the lever until it clicks. Before inhaling the dose, breathe out fully; do not exhale into the Diskus device; activate and use only in a level, horizontal position. Bring mouthpiece to lips and inhale quickly and deeply through the Diskus; hold breath for about 10 seconds or for as long as comfortable and exhale slowly. Do not use with a spacer device or wash mouthpiece; Diskus should be kept dry. The dose indicator tells how many doses are left. When the numbers 5 to 0 appear in red, only a few doses remain, and the pharmacy should be contacted for a refill.</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization: Concentrated solutions (≥0.5%) should be diluted prior to use; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment. Blow-by administration is not recommended; use a mask device if patient is unable to hold mouthpiece in mouth for administration. Compatibility with other medications (eg, budesonide, fluticasone, ipratropium) in nebulizer has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101066','lexi-content-ref-24172851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101066','lexi-content-ref-24172851'])">Ref</a></span>); also refer to institution-specific policies</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not crush or chew extended-release tablets.</p></div>
<div class="block adm drugH1Div" id="F130955"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infusion solution [Canadian product]: Do not inject undiluted. Reduce concentration by at least 50% before infusing. Administer as a continuous infusion via infusion pump.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:4em;">Metered-dose inhalers: Shake well before use; prime prior to first use, and whenever inhaler has not been used for &gt;2 weeks or when it has been dropped, by releasing 3 to 4 test sprays into the air (away from face). Airomir [Canadian product] labeling recommends releasing a minimum of 4 test sprays when priming. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use. A spacer device or valved holding chamber is recommended for use with metered-dose inhalers.</p>
<p style="text-indent:-2em;margin-left:4em;">Dry powder inhalers:</p>
<p style="text-indent:-2em;margin-left:6em;">ProAir Digihaler, ProAir RespiClick: Inhaler device is breath-actuated; does not require priming. Do not use with spacer or volume holding chamber. Keep inhaler clean and dry by wiping with dry cloth or tissue as needed; do not wash or put any part of inhaler in water.</p>
<p style="text-indent:-2em;margin-left:6em;">Ventolin Diskus [Canadian product]: For oral inhalation route only. To activate Diskus, patient should slide lever using the thumb grip away from them as far as it will go (click should be heard). Before inhaling the dose, breathe out fully; do not exhale into the Diskus device. Bring mouthpiece to lips and inhale steadily and deeply through the Diskus; hold breath for about 10 seconds or for as long as comfortable and exhale slowly. To close Diskus slide thumb grip back as far as it will go towards its original position. To prevent a wasted dose, the lever should not be manipulated until administration of next dose. Diskus counts down from 60 to 1 and when 5 doses remain the numbers appear in red. Diskus should be kept dry.</p>
<p style="text-indent:-2em;margin-left:2em;">Nebulization solution: Concentrated solutions (≥0.5%) should be diluted prior to use; adjust nebulizer flow to deliver dosage over 5 to 15 minutes; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment. Blow-by administration is not recommended; use a mask device if patient unable to hold mouthpiece in mouth for administration. Compatibility with other medications (eg, budesonide, fluticasone, ipratropium) in nebulizer has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101066','lexi-content-ref-24172851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101066','lexi-content-ref-24172851'])">Ref</a></span>); also refer to institution-specific policies.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not cut, crush, or chew ER tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.</p></div>
<div class="block sts drugH1Div" id="F130969"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Metered-dose inhalers (HFA aerosols): Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not store at temperature &gt;120°F. Do not puncture. Do not use or store near heat or open flame.</p>
<p style="text-indent:-2em;margin-left:4em;">Proventil HFA: Store with mouthpiece down.</p>
<p style="text-indent:-2em;margin-left:4em;">Ventolin HFA: Discard when counter reads 000. Store with mouthpiece down.</p>
<p style="text-indent:-2em;margin-left:2em;">Dry powder inhalers:</p>
<p style="text-indent:-2em;margin-left:4em;">ProAir Digihaler, ProAir RespiClick: Store between 15°C and 25°C (59°F and 77°F). Avoid exposure to extreme heat, cold, or humidity. Discard 13 months after opening the foil pouch, or when the counter displays 0, whichever comes first.</p>
<p style="text-indent:-2em;margin-left:4em;">Ventolin Diskus [Canadian product]: Store at ≤30°C (86°F). Keep in a dry place. Protect from frost and light. Diskus is nonrefillable and should be discarded after all doses have been administered.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion solution [Canadian product]: Ventolin IV: Store at 15°C to 30°C (59°F to 86°F). Protect from light. After dilution, discard unused portion after 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Nebulization solution: Store at 2°C to 25°C (36°F to 77°F). Do not use if solution changes color or becomes cloudy. Products packaged in foil should be used within 1 week (or according to the manufacturer's recommendations) if removed from foil pouch.</p>
<p style="text-indent:-2em;margin-left:2em;">Syrup: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, extended release: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565230"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of bronchospasm in patients with reversible obstructive airway disease (Syrup: FDA approved in ages ≥2 years and adults; Immediate-release and extended-release tablets: FDA approved in ages ≥6 years and adults). <b>Note:</b> Although an FDA approved indication, the use of oral formulations of albuterol for management of acute asthma or long-term daily maintenance treatment is not recommended due to slower onset of action and higher risk of side effects (GINA 2021; NAEPP 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:4em;">Metered-dose inhaler and dry powder inhaler: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease; prevention of exercise-induced bronchospasm (All indications: FDA approved in ages ≥4 years and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: Treatment of bronchospasm in patients with reversible obstructive airway disease (FDA approved in ages ≥2 years and adults); treatment of acute attacks of bronchospasm (FDA approved in ages ≥2 years and adults). <b>Note:</b> Approved indications and ages may vary by product; consult prescribing information for details.</p></div>
<div class="block mst drugH1Div" id="F131035"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albuterol may be confused with Albutein, atenolol </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proventil may be confused with Bentyl, PriLOSEC, Prinivil</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salbutamol may be confused with salmeterol </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventolin may be confused with phentolamine, Benylin, Vantin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298694"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F130944"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists (Short-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Short-Acting).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta2-Agonists (Short-Acting) may diminish the therapeutic effect of Methacholine.  Management: Hold short-acting beta<sub>2</sub> agonists for 6 hours before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta2-Agonists may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F130961"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Albuterol crosses the placenta (Boulton 1997).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of beta-2 agonists is not associated with an increased risk of fetal malformations (GINA 2023). Systemic use may be associated with hypoglycemia and tachycardia in the mother and fetus (ERS/TSANZ [Middleton 2020]). Albuterol may affect uterine contractility by interacting with beta-2 adrenoceptors in the uterus.</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth and gestational diabetes) (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Albuterol is the preferred short-acting beta-2 agonist (SABA) for the management of asthma during pregnancy (ERS/TSANZ [Middleton 2020]). Pregnant patients should be treated with a SABA for acute asthma exacerbations (GINA 2023). Maternal asthma symptoms should be monitored monthly (ERS/TSANZ [Middleton 2020]; GINA 2023). If high doses of albuterol are required within 48 hours of delivery, monitoring of glucose concentrations in the newborn for 24 hours is recommended, especially in preterm infants (GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Due to effects on uterine contractility, albuterol has been studied as a tocolytic to prevent preterm labor (not an approved use in the United States or Canada). Maternal side effects associated with this use include cardiac arrhythmias, metabolic changes (hypokalemia, hyperglycemia), myocardial ischemia, and pulmonary edema; fetal tachycardia may also occur. Due to the increased risk of adverse events and the availability of safer options, albuterol is not recommended for use as a tocolytic (ACOG 2016; Besinger 1990; Chan 2006; NICE 2015; Sentilhes 2017; WHO 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Healthcare providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (1-877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.</p></div>
<div class="block mopp drugH1Div" id="F53565231"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor asthma symptoms, FEV<sub>1</sub>, peak flow and/or other pulmonary function tests, blood pressure, heart rate, and CNS stimulation; arterial or capillary blood gases (if patient's condition warrants); serum potassium and serum glucose (in selected patients).</p></div>
<div class="block pha drugH1Div" id="F130938"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Relaxes bronchial smooth muscle by action on beta<sub>2</sub>-receptors with little effect on heart rate.</p></div>
<div class="block phk drugH1Div" id="F130957"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: ≤5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation<b>: </b>DPI: 5.7 minutes (median); MDI: 5.4 to 8.2 minutes (median).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate release: ≤30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: 3 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation<b>: </b>DPI: ~2 hours (median); MDI: ~4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate release: 6 to 8 hours; Extended release: Up to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to an inactive sulfate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation: 3.8 to ~5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate release: 5 to 6 hours; Extended release: 9.3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution<b>: </b>30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation: DPI: 30 minutes; MDI: 25 minutes (mean).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate release: ≤2 hours; Extended release: 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, FEV<sub>1</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution<b>: </b>~1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation: DPI: Within 30 minutes; MDI: 47 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate release: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% to 100% [oral inhalation]; 76% over 3 days [60% metabolite; oral]); Feces (&lt;20% [oral inhalation]; 4% [oral]).</p></div>
<div class="block phksp drugH1Div" id="F51219924"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: There was a 67% decline in albuterol clearance in patients with CrCl 7 to 53 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F130963"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Asmadil | Asmanore | Asthalin | Asthavent | Asthavent dp | Butalin | Butovent | Disbron | Farcolin | Neoventil | Salamol | Vental | Ventamol | Ventol | Ventolin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aerolep | Aircosalm | Aircosalm hfa | Airsalbu | Amocasin | Asmatol | Asmatol hfa | Butamol | Cercini | Duopack | Labsavent | Microterol | Nebutrax | Niblet | Respiret klonal | Salbuden | Salbuden con aerocamara df | Salbutamol | Salbutamol denver farma | Salbutamol fabra | Salbutamol kilab | Salbutamol lacefa | Salbutamol lafedar | Salbutamol Pharma | Salbutamol richet | Salbutol | Salbutral | Salbutral c/aeromed | Ventolin | Yontal | Zoom</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Salbutamol sandoz | Sultanol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Apo salbutamol | Asmol | Epaq | Respax | Respolin | Ventolin | Zempreon</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Absol | Actolin | Alvolex | Asmalin hfa | Asmatol | Asmolex | Asnil | Asthmarol | Asthmolin | Asul | Azmasol | Bitol | Broad | Brodil | Brolax | Broncodil | Broncolin | Bronkolax | Butalin | Butamol | Butol | D-Butamol | Decabutamol | Dilatol | G-salbutamol | Jp salbo | Koptolin | Pulmocare | Pulmolin | Respolin | Reven | Salbo | Salbu | Salbunil | Salbusol | Salbut | Salbutal | Salbutamol | Salmol | Salmolin | Saltide | Sulbutamol | Sultolin | Sultolin hfa | Tolin | Venol | Ventisal | Ventol | Ventolex | Ventolin | Windel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Docsalbuta | Ecosal Easi Breath | Salbutamol sandoz | Ventolin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Asthalin | Buto Asma | Salbutus | Tamuxxair | Ventoline | Ventoline rotacaps</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Buto-Asma | Ecosal | Salamol | Salbutamol | Ventolin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acobelin | Aero ifal | Aero-ped | Aeroclean | Aerodini | Aerofrin | Aerogold | Aerogreen | Aerojet | Aerolin | Aeromed | Aerotamol | Aerotrat | Albulin | Asmaflux | Asmakil | Asmaliv | Broncofedrin | Broncomix | Bronconal | Butalab | Butovent | Dilamol | Lafepe salbutamol | Neutoss | Pulmoflux | Regrair | Salburin | Salbutalin | Salbutam | Salbutamax | Salrolin | Saltamol | Sarolin | Sulfato de salbutamol | Teoden | Tussiliv</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ecovent | Salamol | Ventodisk | Ventolin | Ventolin zuckerfrei mit saccharin | Volmax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Aerol | Asthalin | Broncoron | Salbutus | Ventoline rotacaps</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aero-sal | Aerolin | Astin | Broncoterol | Bropil | Butotal | Fesema | Respiret | Respolin | Sacrusyt | Salbusev | Salbutamol | Salbutral | Salbutral hfa | Sinasmal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai sha xi le | Cyclocaps | Da fen ke chuang | Hui bai shi | Pin chuan | Salbutamol | Sha pu er | Shuan shu ning | Ventolin | Volmax | Wan tuo lin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Airmax | Asmepoc | Asthalin Hfa | Axpira | Bajapres | Bentusol | Benylan | Betadren | Bonair | Bronter | Brotamol | Bugonol | Butotal | Ciplabutol | Deltabutol | Friotan | Neumoterol | Parasma | Rexpirex | Sacrusyt | Salbumed | Salburex | Salbutamol | Salbutamol mk | Salbutamol MK | Salbutan | Servitamol | Solbucort | Ventilan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Asmaven | Asthalin | Buventol | Ecosal | Salbumol | Salbutamol | Ventolin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Aerolind | Apsomol | Apsomol n | Broncho | Bronchospray | Loftan | Paediamol | Salbu | Salbu-fatol | Salbuhexal | Salbuhexal N | Salbupur d | Salbupur e | Salbusandoz | Salbutamol | Salbutamol 1 A Pharma | Salbutamol al | Salbutamol CT | Salbutamol sandoz | Salbutamol stada | Salbutamol Trom | Salbutamol-ratiopharm n | Salvent | Sultanol | Volmac</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Airplen | Albugenol | Alunic | Amocasin | Asthalin | Astumol | Broncomat | Broncosamol | Buto air | Buto Asma | Butovent | Dilabron | Elbutamol | Frabutamol | Lascobutamol | Nebusol | Respiret | Salbucyma | Salbufar | Salbulin | Salbumox | Salbutamol | Salbutamol Feltrex | Salbutan | Salbutol | Salbutral | Salcrymol | Salventil | Ventolin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Airmax | Airplen | Bemin | Broncoterol | Butotal | Ciplabutol | Ecutamol | Krosalburol | Nebulasma | Salbutamol | Salbutamol Ecar | Salbutamol MK | Salbutamol mk | Salden | Ventolin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Buventol | Ecosal | Ecosal easi-breath | Salbutamol ratiopharm | Salbutamol-dynapharm | Salbuvent | Ventolin | Volmax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Albuterol | Asthmarelief | Broncholin s | Bronchoterol | Bronchovent | Butalin | Farcolin | Mepacovent | Octovent | Salbovent | Salbuline | Salbutamol | Vental | Ventene | Ventolin | Viasalmol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aldobronquial | Bronsal | Buto air | Buto Asma | Dipulmin | Emican | Salbutamol aldo union | Salbutamol sandoz | Ventiloboi | Ventoaldo | Ventolin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Albuterol | Lebasma | Salbutamol | Salbutamol sulphate | Ventolin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Buventol | Salbumol | Ventoline</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Salbumol | Spreor | Ventexxair | Ventoline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Airsalb | Asmasal | Asmavent | Cobutolin | Libetist | Salamol | Salapin | Salbulin | Salbutamol | Salbutamol Berk | Salbutamol Ivax | Salbutamol sandoz | Ventolin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Asthmotrate | Normobron | Normobron pulvinal | Salbunova | Salbutamol | Salomol | Ventolin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Apo-salvent | Asmalin | Asmovent | Asthalin Hfa | Axcel Salbutamol | Azmacon | Azmasol | Buto Asma | Cybutol | Eurotolin | Medolin | Respolin | Respreve | Salamol | Salbutamol | Salmol | Saltalin | Salven | Solia | Syntalin | Synvent hfa 100 | Uni-Butamol | Vantin | Ventamol | Venteze | Ventolin | Zenmolin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Salbutamol Pliva | Ventolin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ac-butamol | Ecosal | Huma-salmol | Salbutamol | Ventolin | Volmax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Asmacare | Asmacel | Astharol | Azmacon | Brondisal | Cybutol | Dilatamol | Dipsamol | Fartolin | Glisend | Grafalin | Lasal | Librentin | Pritasma | Respolin | Salbron | Salbulin | Salbutamol | Salbuven | Saltam | Suprasma | Venterol | Ventolin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Gerivent | Salamol | Salbul | Salbutamol | Salomol | Ventamol | Ventolin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apovent | Ventolin | Volmax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aerotaz | Alsal | Asmanil | Asthalin | Asthalin Hfa | Asthalin sa | Astinol | Bemol | Broncocet | Bronko | Bronkonat | Brosol | Derihaler | Durasal | Frespire | Lebasma | Pertulyn | Rheolin | Salbair | Salbetol | Salbid | Salbusun | Salbutamol | Salbutas | Salmaplon | Somavent | Sos | Vent | Ventamol | Ventil | Ventisol | Ventorlin | Ventryl</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Buetarin d | Butadil j | Butadin | Butamol | Nutadeen | Salbutamol | Salbutin | Salutin | Venolin mdi | Ventalen | Ventodad | Ventomel</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aerotec | Broncovaleas | Salbufax | Salbutamolo Sandoz | Ventolin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Asmadil | Asmanor | Asthalin | Butalin | Butovent | Medolin | Salbutis | Vental | Ventol | Ventolin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Asmidon | Asu tajisu | Benareal | Renapirin | Saltan | Sultanol | Tivoline | Venetlin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asbutol | Asmeez | Astalin | Asthadin | Asthalin | Axamol | Azmasol | Bonair | Brodil hfa | Bronchomol | Butin | Derihaler | Lastmol | Liscoril | Medisalant | Sabulin | Salbucort | Salbumol | Salbut | Salbutamol | Salfil | Statasmin | Sultolin hfa | Tabusol | Tavent | Venteze | Ventil | Ventolin | Ventomol | Ventosal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Respolin | Salbutamol | Salbutamol bkw | Salbutol | Ventolin | Ventolin respirator</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Butalin | Neoventil | Salamol | Salbucare | Salbutamed | Vental | Ventol | Ventolin | Ventomax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aloprol | Asmalat | Butalin | Buto Asma | Butovent | Neoventil | Salbutamol | Ventolin | Volmax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Asmaven | Asthalin | Astmasol | Ecosal | Salamol | Salbutamol | Salbutamol eipico | Salbutamol inteli | Salbuvent | Ventodisk | Ventolin | Volmax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Ventolin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Asmaven | Asthalin | Astmasol | Salamol | Salbutamol | Salbutamol inteli | Salbutamol maxpharma | Salbuvent | Sultanol | Ventolin | Volmax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aerol | Bulmol | Butamyl | Butovent | Dilator | Inaler | Servitamol | Ventoline</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alisal | Aposalvent | Assal | Avedox fc | Avendox fc | Azyrol | Biorenyn | Bresaltec | Brusal | Capacit | Cobamol | Exafil | Farmarest | Inbumed | Iqfavent | Nebsal | Quinfaval | Rodribrak | Sacrusyt | Salamol | Salbutalan | Salbutamol | Salbutamol boehringer | Salbutamol gi | Salbutamol gi arle | Salbutamol gi brul | Salbutamol gi merc | Salbutamol gi salu | Salbutamol protein | Salbutamol ultra | Salbutamol wyeth | Salbutamol zerboni | Salcomed | Sofamix | Tunxin | Unibron | Ventilan | Ventolin | Zibil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Anasma | Asmaliv | Asmin | Asmol | Asthalin | Asthavent | Axcel Salbutamol | Azmasol | Beatolin | Biomol | Bonair | Breathnine | Brethmol | Broncolin | Butahale | Butavent | Butovent | Healol salbutamol | Medolin | Rescanil | Salamol | Salbutamol | Salmax | Salmol | Saltoline | Ventamol | Ventolin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Afrab salbutamol | Asmacof p | Asthalin | Axcel salbutamol | Azmasol | Bexilin | Bleornol | Bonair | Farmex salbutamol | Greenhope salbutamol | Kinzolin | Sabumalin | Salbutamol | Suretolin | Zotrex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Airomir | Salbutamol | Salbutamol A | Salbutamol actavis | Salbutamol CF | Salbutamol cyclocaps | Salbutamol pch | Salbutamol redihaler | Salbutamol sandoz | Salbutamol Teva | Ventolin | Ventolin es</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Airomir | Salbutamol eipico | Ventilan | Ventolin | Ventoline</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Asmol | Broncolin | Respigen | Respolin | Salair | Salamol | Salbutamol | Ventolin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acteril | Aeroler | Aircosalm hfa | Airplen | Apo-salvent | Asthalin | Broncobutol | Bronquimax | Butahale | Butotal | Pectolin | Salbid | Salbubronc | Salbusev hfa | Salbutam | Salbutamo | Salbutamol | Salbutex | Salbutol | Salbutral | Salbutrin | Salbuvent | Servitamol | Sultadrin | Ventimax | Ventolin | Ventusol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Activent | Airhexal | Airomir | Airsal | Albulem | Amoltex | Arbados | Asbunyl | Asfrenon | Asmacaire | Asmafort | Asmalin | Asmamed | Asmar | Asmarex | Astagen | Asthmagen | Asvimol | Axmaxolv | Azmasol | Beisol | Bioxal | Boie Salbutamol | Breezol | Broncaire | Broncolin | Bronelid | Brytolin | Butadil | Butovent | Cletal | Derihaler | Efamed | Emplusal | Gloleen | Hivent | Librentin | Medic aid salbutamol | Meventil | Mgl-salbutamol | Nobutol | Primesal | Prox-s | Resdil | Resovent | Respolin | Sal | Salbuflo | Salbuhaler | Salbumed | Salbumin | Salbusol | Salbutamol | Salbutamol Am-Europharma | Salbutamol Myrex | Salbutamol Pacific | Salbuvan | Salmate | Saltal 4 | Salvex | Sedalin | Socamol | Solben | Theoryl | Turbolax | Venalax | Vencronyl | Vent | Ventar | Vento-broncho | Ventolax | Ventolin | Ventomax | Ventosal | Ventress | VN2</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Aerotec | Asmatol | Asthamol | Asthavent | Blissbronchal | Breathmore | Bronchilate | Broncolin | Bronkal | Broven | Butamin | Butamol | Butoasma | Butovent | Erobolin | Eulin | Faktolin | Inhalerin | Inspirol | Radisal | Respilax | Respolin | Salbair | Salbax | Salbest | Salbo | Salbovent | Salbree dpi | Salbuhaler | Salmol | Venex | Ventiplus | Ventolin | Ventopharm | Ventosal | Wintol | Zaftolin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Albuterol | Aspulmo | Sabumalin | Salamol eb | Salbutamol | Salbuvent | Velaspir | Ventolin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Albuterol | Albuterol Hfa | Albuterol sulfate | Albuterol sulfate hfa | Proventil | Proventil hfa | Ventolin | Ventolin hfa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Prodome | Salbutamol Generis | Salbutamol GP | Salbutamol sandoz | Ventilan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acteril | Acteril plus | Aircosalm hfa | Asmavent sf | Asmazol | Asthalin | Broncofil | Brondil plus | Butamol | Codetamol | Lung | Respiral | Respiran | Salbutamol caplin point | Salbutamol dutriec | Salbutamol empa | Salbutamol genfar | Salbutamol imedic | Salbutamol la sante | Salbutamol pasteur | Salbutamol v y t farma | Salbutamol vyt farma | Salbutol | Salbutolin | Salbutral | Sinasmal | Sinasmal sf | Tarison | Ventilex | Ventiplus | Ventolin | Zoom</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Asthalin | Asthavent | Asthavent Respules | Breathnine | Butalin | Farcolin | Neoventil | Salbo HFA | Salbolin | Ventol | Ventolin | Ventolin Diskus | Ventolin Evohaler | Ventolin Nebules | Ventolin Respirator</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Farcolin | Salbutamol eipico | Ventolin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Astalin | Asthalin | Cybutol cyclocaps | Gen salbutamol | Novatron | Novatron neo | Salamol | Salamol easy breat | Salamol eco | Salamol eco easy breath | Salbutamol | Salbutamol aeronativ | Salbutamol air | Salbutamol av | Salbutamol mhfp | Salbutamol pharmstandart | Salbutamol Teva | Salbuvent | Salgim | Saltos | Ventocol | Ventodisk | Ventolin | Vertasort | Volmax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Asmadil | Asmanore | Asthalin | Asthavent | Butalin | Butovent | Disbron | Farcolin | Neoventil | Salamol | Salbulase | Salbutamed | Ventolin | Ventolin cr | Vintec</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Sabufarm | Salbutamol Scand Pharm | Salbuvent | Ventoline</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-salvent | Asmol | Azmasol | Butahale | Buto-Asma | Medolin | Sabutol | Salamol | Salbuair | Salbutamol | Salmol | Unisabmol | Venderol | Ventamol | Ventolin | Zenmolin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ventolin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ecosal | Salamol | Salbutamol | Ventodisk | Ventolin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Chemolin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aeromol | Aerotamol | Antomol | Asmasal | Asmatol | Asmatum | Asmo | Asmol | Asthalin | Asthamol | Asthma | Asthmolin | Bocoma | Bonair | Bronchodyl | Bronchosol | Butamol | Buto-asma inhaler | Butovent | Cintamol | Kressvent | Medolin | N-tolin | Naso | Natolin | Respolin | Sabumol | Saburin | Salamol | Salbetol | Salbulin | Salbusian | Salbutac | Salbutamol | Salbuvent | Salda | Saldol | Salmodon | Salmol | Saltalin | Saltolin | Satalin | Servitamol | Solia | Starbumol | Tanalin | Venbumed | Venbumol | Venbutin | Venline | Venmed | Ventamed | Venterol | Ventolin | Violin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Albutol | Asmadil | Butalin | Butovent | Salbutamol | Salbuvent | Ventmax | Ventoline</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Asthavent | Brecur | Butovent | Salbulin | Salbutol | Salres | Vent o sal | Ventolin | Ventosal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Albuterol | Albutol | Astamol | Bentolin | Censolin | Cotran | Mozal | Nopant | Respolin | Sabuchan | Sabumol | Sabutal | Sadamol | Salamol | Salbumol | Salbutain | Salbutamo | Salbutamol | Salbutamol "c.h." | Salbutan | Salbutol | Salbuvent | Salmol | Saltmol | Saltol | Saltolin | Salutol | Samol | Satamol | Sucotin | Sunling | Synvent hfa | Ventolin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aerolin | Asthalin | Brutamol | Nebutamol | Salamol | Salamol Easy Breath | Salamol eco | Salbutamol | Salbutamol neo | Salbuvent | Ventolin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agobutol | Agolin | Asbutol | Asthalin | Astharen | Azmasol | Kam vent | Lebasma | Sabulin | Salbumol | Salbut | Salres | Ventolin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Asmatol | Butovent | Raudosal | Respiran | Salbulin | Salbutamol Winpharm | Salbutral | Tarison | Ventiplus | Ventolin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aerodini | Albutan | Asthalin | Butahale | Butoas | Diadilat | Respolin hfa | Sacrusyt | Salbuden | Salbulis | Salbumed | Salburol | Salbutamol | Salbutamol aldo union | Salbutan | Salres | Sultolin | Ventolin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Hasalbu | Pro salbutamol | Salbuboston | Zensalbu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Airomir | Asthalin | Asthavent | Cybutol | Glenbute | Saasth | Salbulin | Vari salbutamol | Venteze | Ventimax | Ventolin | Viavent</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Asthalin | Asthamol | Lastmol | Lebasma | Mestil | Sabulin | Salbair | Salbamol | Salbukant | Salbuta | Salbutamol | Salfil | Salmol | Samaol | Samol | Statasmin | Ventamol | Venteze | Ventolin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Asmanol | Asthalin | Salbutamol | Venteze | Ventolin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Airomir.1">
<a name="Airomir.1"></a>Airomir (salbutamol) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albuterol.1">
<a name="Albuterol.1"></a>Albuterol sulfate inhalation solution 0.5% [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albuterol.3">
<a name="Albuterol.3"></a>Albuterol sulfate inhalation solution [prescribing information]. Columbia, SC: The Ritedose Corporation; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albuterol.4">
<a name="Albuterol.4"></a>Albuterol sulfate inhalation solution 0.021% and 0.042% [prescribing information]. Columbia, SC: The Ritedose Corp; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albuterol.6">
<a name="Albuterol.6"></a>Albuterol sulfate syrup [prescribing information]. Lincolnton, NC: Cosette Pharmaceuticals Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albuterol.8">
<a name="Albuterol.8"></a>Albuterol sulfate extended-release tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; March 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Albuterol.10">
<a name="Albuterol.10"></a>Albuterol sulfate tablet [prescribing information]. Congers, NY: Chartwell RX LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2266671">
<a name="2266671"></a>Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. <i>Kidney Int</i>. 1990;38(5):869-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2266671/pubmed" id="2266671" target="_blank">2266671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2919849">
<a name="2919849"></a>Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. <i>Ann Intern Med</i>. 1989;110(6):426-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2919849/pubmed" id="2919849" target="_blank">2919849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27661654">
<a name="27661654"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 171: management of preterm labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published January 2021. Accessed June 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8058420">
<a name="8058420"></a>Avital A, Godfrey S, Schachter J, Springer C. Protective effect of albuterol delivered via a spacer device (Babyhaler) against methacholine induced bronchoconstriction in young wheezy children. <i>Pediatr Pulmonol</i>. 1994;17(5):281-284. doi:10.1002/ppul.1950170503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8058420/pubmed" id="8058420" target="_blank">8058420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11749685">
<a name="11749685"></a>Ballard J, Lugo RA, and Salyer JW, "A Survey of Albuterol Administration Practices in Intubated Patients in the Neonatal Intensive Care Unit," <i>Respir Care</i>, 2002, 47(1):31-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11749685/pubmed" id="11749685" target="_blank">11749685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7755840">
<a name="7755840"></a>Bartfield JM, Boenau IB, Lozon J, et al, “Comparison of Metered Dose Inhaler and Oral Administration of Albuterol in the Outpatient Treatment of Infants and Children,” <i>Am J Emerg Med</i>, 1995, 13(3):375-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/7755840/pubmed" id="7755840" target="_blank">7755840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35658162">
<a name="35658162"></a>Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalemia in adults. <i>Cochrane Database Syst Rev</i>. 2015;10:CD010344. doi: 10.1002/14651858.CD010344.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/35658162/pubmed" id="35658162" target="_blank">35658162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15334507">
<a name="15334507"></a>Bentur L, Mansour Y, Hamzani Y, Beck R, Elias N, Amirav I. Measurement of inspiratory flow in children with acute asthma. <i>Pediatr Pulmonol</i>. 2004;38(4):304-307. doi:10.1002/ppul.20109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/15334507/pubmed" id="15334507" target="_blank">15334507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berkovitch.1">
<a name="Berkovitch.1"></a>Bercovitch RS, Tsai SC. Respiratory medications and sleep. <i>Curr Respir Care Rep</i>. 2012;1:123-130. doi:10.1007/s13665-012-0013-1</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2195409">
<a name="2195409"></a>Besinger RE, Niebyl JR. The safety and efficacy of tocolytic agents for the treatment of preterm labor. <i>Obstet Gynecol Surv</i>. 1990;45(7):415-440. doi:10.1097/00006254-199007000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2195409/pubmed" id="2195409" target="_blank">2195409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17166990">
<a name="17166990"></a>Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. <i>Chest</i>. 2006;130(6):1733-1743. doi:10.1378/chest.130.6.1733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/17166990/pubmed" id="17166990" target="_blank">17166990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24089311">
<a name="24089311"></a>Bonini M, Di Mambro C, Calderon MA, et al. Beta₂-agonists for exercise-induced asthma. <i>Cochrane Database Syst Rev</i>. 2013;(10):CD003564. doi: 10.1002/14651858.CD003564.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24089311/pubmed" id="24089311" target="_blank">24089311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9431837">
<a name="9431837"></a>Boulton DW, Fawcett JP, and Fiddes TM, "Transplacental Distribution of Salbutamol Enantiomers at Caesarian Section," <i>Br J Clin Pharmacol</i>,1997, 44(6):587-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9431837/pubmed" id="9431837" target="_blank">9431837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BTS.1">
<a name="BTS.1"></a>British Thoracic Society (BTS). BTS/SIGN British guideline on the management of asthma. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Updated 2019. Accessed January 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101066">
<a name="20101066"></a>Burchett DK, Darko W, Zahra J, Noviasky J, Probst L, Smith A. Mixing and compatibility guide for commonly used aerosolized medications. <i>Am J Health Syst Pharm.</i> 2010;67(3):227-230. doi:10.2146/ajhp080261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/20101066/pubmed" id="20101066" target="_blank">20101066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11413357">
<a name="11413357"></a>Burggraaf J, Westendorp RG, in't Veen JC, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. <i>Thorax</i>. 2001;56(7):567-569. doi:10.1136/thorax.56.7.567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11413357/pubmed" id="11413357" target="_blank">11413357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Campbell.1">
<a name="Campbell.1"></a>Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24599614">
<a name="24599614"></a>Carroll CL, Coro M, Cowl A, Sala KA, Schramm CM. Transient occult cardiotoxicity in children receiving continuous beta-agonist therapy. <i>World J Pediatr</i>. 2014;10(4):324-329. doi:10.1007/s12519-014-0467-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24599614/pubmed" id="24599614" target="_blank">24599614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23537669">
<a name="23537669"></a>Carroll CL, Sala KA. Pediatric status asthmaticus. <i>Crit Care Clin</i>. 2013;29(2):153-166. doi:10.1016/j.ccc.2012.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/23537669/pubmed" id="23537669" target="_blank">23537669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16060696">
<a name="16060696"></a>Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. <i>Drugs</i>. 2005;65(12):1595-1610. doi:10.2165/00003495-200565120-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/16060696/pubmed" id="16060696" target="_blank">16060696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371312">
<a name="19371312"></a>Cekici L, Valipour A, Kohansal R, Burghuber OC. Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study. <i>Br J Clin Pharmacol</i>. 2009;67(4):394-402. doi:10.1111/j.1365-2125.2009.03377.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/19371312/pubmed" id="19371312" target="_blank">19371312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15219010">
<a name="15219010"></a>Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. [published correction appears in <i>Eur Respir J</i>. 2006;27(1):242]. <i>Eur Respir J</i>. 2004;23(6):932-946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/15219010/pubmed" id="15219010" target="_blank">15219010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16504369">
<a name="16504369"></a>Chan J, Cabrol D, Ingemarsson I, Marsal K, Moutquin JM, Fisk NM. Pragmatic comparison of beta2-agonist side effects within the worldwide atosiban versus beta agonists study. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2006;128(1-2):135-141. doi:10.1016/j.ejogrb.2006.01.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/16504369/pubmed" id="16504369" target="_blank">16504369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211074">
<a name="22211074"></a>Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/22211074/pubmed" id="22211074" target="_blank">22211074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8181328">
<a name="8181328"></a>COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. <i>Chest</i>. 1994;105(5):1411-1419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8181328/pubmed" id="8181328" target="_blank">8181328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7634874">
<a name="7634874"></a>Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE. Impaired bronchodilator response to albuterol in healthy elderly men and women. <i>Chest</i>. 1995;108(2):401-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/7634874/pubmed" id="7634874" target="_blank">7634874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24139581">
<a name="24139581"></a>Daly K, Farrington E. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment. <i>J Pediatr Health Care</i>. 2013;27(6):486-498. doi:10.1016/j.pedhc.2013.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24139581/pubmed" id="24139581" target="_blank">24139581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16421365">
<a name="16421365"></a>Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. <i>N Engl J Med</i>. 2006;354(3):241-250. doi:10.1056/NEJMoa043891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/16421365/pubmed" id="16421365" target="_blank">16421365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17662398">
<a name="17662398"></a>Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS. Four-year recurrence rate and prognosis of the apical ballooning syndrome. <i>J Am Coll Cardiol</i>. 2007;50(5):448-452. doi:10.1016/j.jacc.2007.03.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/17662398/pubmed" id="17662398" target="_blank">17662398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.2">
<a name="Fanta.2"></a>Fanta CH, Cahill KN. Acute exacerbations of asthma in adults: Emergency department and inpatient management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 4, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.3">
<a name="Fanta.3"></a>Fanta CH, Cahill KN. Acute exacerbations of asthma in adults: Home and office management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 13, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.1">
<a name="Fanta.1"></a>Fanta CH, Lange-Vaidya N. Treatment of intermittent and mild persistent asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9828734">
<a name="9828734"></a>Fok TF, Lam K, Ng PC, et al, "Randomised Crossover Trial of Salbutamol Aerosol Delivered by Metered Dose Inhaler, Jet Nebuliser, and Ultrasonic Nebuliser in Chronic Lung Disease," <i>Arch Dis Child Fetal Neonatal Ed</i>, 1998, 79(2):F100-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9828734/pubmed" id="9828734" target="_blank">9828734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377880">
<a name="28377880"></a>George M, Joshi SV, Concepcion E, Lee H. Paradoxical bronchospasm from benzalkonium chloride (BAC) preservative in albuterol nebulizer solution in a patient with acute severe asthma. A case report and literature review of airway effects of BAC. <i>Respir Med Case Rep</i>. 2017;21:39-41. doi:10.1016/j.rmcr.2017.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/28377880/pubmed" id="28377880" target="_blank">28377880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Updated 2021. Accessed May 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grammer.1">
<a name="Grammer.1"></a>Grammer LC. Idiopathic anaphylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19219329">
<a name="19219329"></a>Grotta MB, Etchebere EC, Ribeiro AF, Romanato J, Ribeiro MA, Ribeiro JD. Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. <i>J Bras Pneumol</i>. 2009;35(1):35-43. doi:10.1590/s1806-37132009000100006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/19219329/pubmed" id="19219329" target="_blank">19219329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11861242">
<a name="11861242"></a>Hadjikoumi I, Loader P, Bracken M, Milner AD. Bronchodilator therapy and hyperactivity in preschool children. <i>Arch Dis Child</i>. 2002;86(3):202-203. doi:10.1136/adc.86.3.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11861242/pubmed" id="11861242" target="_blank">11861242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8118539">
<a name="8118539"></a>Hickey RW, Gochman RF, Chande V, Davis HW. Albuterol delivered via metered-dose inhaler with spacer for outpatient treatment of young children with wheezing. <i>Arch Pediatr Adolesc Med</i>. 1994;148(2):189-194. doi:10.1001/archpedi.1994.02170020075013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8118539/pubmed" id="8118539" target="_blank">8118539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24509059">
<a name="24509059"></a>Horikawa YT, Udaka TY, Crow JK, Takayama JI, Stein MT. Anxiety associated with asthma exacerbations and overuse of medication: the role of cultural competency.<i> J Dev Behav Pediatr</i>. 2014;35(2):154-157. doi:10.1097/DBP.0000000000000029. Erratum in:<i> J Dev Behav Pediatr</i>. 2014;35(3):227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24509059/pubmed" id="24509059" target="_blank">24509059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24172851">
<a name="24172851"></a>Kamin W, Erdnüss F, Krämer I. Inhalation solutions--which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers--update 2013. <i>J Cyst Fibros.</i> 2014;13(3):243-250. doi:10.1016/j.jcf.2013.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24172851/pubmed" id="24172851" target="_blank">24172851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kang.1">
<a name="Kang.1"></a>Kang SK. Diagnosis and treatment of an acute reaction to a radiologic contrast agent. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27793870">
<a name="27793870"></a>Khwaja YH, Tai JM. Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation. <i>BMJ Case Rep</i>. 2016;2016:bcr2016217364. doi:10.1136/bcr-2016-217364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/27793870/pubmed" id="27793870" target="_blank">27793870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9170015">
<a name="9170015"></a>Kim HJ. Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients. <i>J Korean Med Sci</i>. 1997;12(2):111-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9170015/pubmed" id="9170015" target="_blank">9170015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23364383">
<a name="23364383"></a>Krebs SE, Flood RG, Peter JR, Gerard JM. Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department. <i>Pediatr Emerg Care</i>. 2013;29(2):191-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/23364383/pubmed" id="23364383" target="_blank">23364383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472998">
<a name="26472998"></a>Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: special circumstances of resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S501-S518. doi:10.1161/CIR.0000000000000264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/26472998/pubmed" id="26472998" target="_blank">26472998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24364481">
<a name="24364481"></a>Lee H, Kim J, Tagmazyan K. Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines. <i>Am Fam Physician</i>. 2013;88(10):655-663, 663B-663F.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24364481/pubmed" id="24364481" target="_blank">24364481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21181208">
<a name="21181208"></a>Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384. doi:10.1007/s00467-010-1699-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/21181208/pubmed" id="21181208" target="_blank">21181208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8285977">
<a name="8285977"></a>Leikin JB, Linowiecki KA, Soglin DF, et al, “Hypokalemia After Pediatric Albuterol Overdose: A Case Series,” <i>Am J Emerg Med</i>, 1994, 12(1):64-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8285977/pubmed" id="8285977" target="_blank">8285977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lemanske.1">
<a name="Lemanske.1"></a>Lemanske RF Jr. Beta agonists in asthma: Acute administration and prophylactic use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852924">
<a name="32852924"></a>Lindner G, Burdmann EA, Clase CM, et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. <i>Eur J Emerg Med</i>. 2020;27(5):329-337. doi:10.1097/MEJ.0000000000000691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/32852924/pubmed" id="32852924" target="_blank">32852924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30297688">
<a name="30297688"></a>Magee JS, Pittman LM, Jette-Kelly LA. Paradoxical bronchoconstriction with short-acting beta agonist. <i>Am J Case Rep</i>. 2018;19:1204-1207. doi:10.12659/AJCR.910888<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/30297688/pubmed" id="30297688" target="_blank">30297688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25981113">
<a name="25981113"></a>Maggini V, Lombardi N, Lenti MC, et al. A case of pediatric Steven-Johnson Syndrome associated with albuterol consumption. <i>Int Immunopharmacol</i>. 2015;27(1):154-155. doi:10.1016/j.intimp.2015.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/25981113/pubmed" id="25981113" target="_blank">25981113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mahajan.1">
<a name="Mahajan.1"></a>Mahajan M, Tucker J, and Dolgin J, “Protocol for Management of Accidental Pediatric Albuterol Ingestions,” <i>Vet Hum Toxicol</i>, 1994, 36:361.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10084465">
<a name="10084465"></a>Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? how safe? <i>Chest.</i> 1999;115(3):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/10084465/pubmed" id="10084465" target="_blank">10084465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8748438">
<a name="8748438"></a>Martin W, Unützer J, Szuba MP. Exacerbation of psychosis associated with inhaled albuterol. <i>J Clin Psychopharmacol</i>. 1995;15(6):446-447. doi:10.1097/00004714-199512000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8748438/pubmed" id="8748438" target="_blank">8748438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21920871">
<a name="21920871"></a>Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. <i>Arch Dis Child</i>. 2012;97(4):376-380. doi:10.1136/archdischild-2011-300623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/21920871/pubmed" id="21920871" target="_blank">21920871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8129434">
<a name="8129434"></a>McClure RJ, Prasad VK, Brocklebank JT. Treatment of hyperkalaemia using intravenous and nebulised salbutamol. <i>Arch Dis Child</i>. 1994;70(2):126-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8129434/pubmed" id="8129434" target="_blank">8129434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19598281">
<a name="19598281"></a>Mhanna MJ, Patel JS, Patel S, et al, "The Effects of Racemic Albuterol Versus Levalbuterol in Very Low Birth Weight Infants," <i>Pediatr Pulmonol</i>, 2009, 44(8):778-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/19598281/pubmed" id="19598281" target="_blank">19598281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ task force statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi: 10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969785">
<a name="1969785"></a>Morgan DJ. Clinical pharmacokinetics of beta-agonists. <i>Clin Pharmacokinet</i>. 1990;18(4):270-294. doi:10.2165/00003088-199018040-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/1969785/pubmed" id="1969785" target="_blank">1969785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10725956">
<a name="10725956"></a>Mutlu GM, Moonjelly E, Chan L, Olopade CO. Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta 2-agonists containing edetate disodium. <i>Mayo Clin Proc</i>. 2000;75(3):285-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/10725956/pubmed" id="10725956" target="_blank">10725956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16002915">
<a name="16002915"></a>Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. <i>Chest</i>. 2005;128(1):48-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/16002915/pubmed" id="16002915" target="_blank">16002915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.2">
<a name="NAEPP.2"></a>National Asthma Education and Prevention Program (NAEPP). 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. NIH Publication No. 20-HL-8140. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; December 2020. <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" target="_blank">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a>. Accessed December 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. NICE guideline [NG25]: Preterm labour and birth. https://www.nice.org.uk/guidance/ng25?unlid=9291036072016213201257. Published November 20, 2015. Updated June 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23798903">
<a name="23798903"></a>Nievas IF, Anand KJ. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. <i>J Pediatr Pharmacol Ther</i>. 2013;18(2):88-104. doi:10.5863/1551-6776-18.2.88<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/23798903/pubmed" id="23798903" target="_blank">23798903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OByrne.1">
<a name="OByrne.1"></a>O'Byrne PM. Exercise-induced bronchoconstriction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3389861">
<a name="3389861"></a>O'Callaghan C, Milner AD, and Swarbrick A, “Nebulized Salbutamol Does Have a Protective Effect on Airways in Children Under One Year Old,” <i>Arch Dis Child</i>, 1988, 63(5):479-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/3389861/pubmed" id="3389861" target="_blank">3389861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30282664">
<a name="30282664"></a>Orth LE, Kelly BJ, Lagasse CA, Collins SW, Ryan MF. Safety and effectiveness of albuterol solutions with and without benzalkonium chloride when administered by continuous nebulization. <i>Am J Health Syst Pharm</i>. 2018;75(22):1791-1797. doi:10.2146/ajhp180154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/30282664/pubmed" id="30282664" target="_blank">30282664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22702533">
<a name="22702533"></a>Papadopoulos NG, Arakawa H, Carlsen KH, et al. International consensus on (ICON) pediatric asthma. <i>Allergy</i>. 2012;67(8):976-997. doi:10.1111/j.1398-9995.2012.02865.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/22702533/pubmed" id="22702533" target="_blank">22702533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23634861">
<a name="23634861"></a>Parsons JP, Hallstrand TS, Mastronarde JG, et al; American Thoracic Society Subcommittee on Exercise-induced Bronchoconstriction. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction.<i> Am J Respir Crit Care Med</i>. 2013;187(9):1016-1027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/23634861/pubmed" id="23634861" target="_blank">23634861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24855502">
<a name="24855502"></a>Patel B, Assad D, Wiemann C, Zughaib M. Repeated use of albuterol inhaler as a potential cause of Takotsubo cardiomyopathy. <i>Am J Case Rep</i>. 2014;15:221-225. doi: 10.12659/AJCR.890388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/24855502/pubmed" id="24855502" target="_blank">24855502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31676529">
<a name="31676529"></a>Patel SJ, Teach SJ. Asthma. <i>Pediatr Rev</i>. 2019;40(11):549-567. doi:10.1542/pir.2018-0282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/31676529/pubmed" id="31676529" target="_blank">31676529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32165556">
<a name="32165556"></a>Pertzborn MC, Prabhakaran S, Abu-Hasan M, Baker D, Wu S, Wu Y, Hendeles L. Continuous albuterol with benzalkonium in children hospitalized with severe asthma. <i>Pediatrics</i>. 2020;145(4):e20190107. doi:10.1542/peds.2019-0107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/32165556/pubmed" id="32165556" target="_blank">32165556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peters.1">
<a name="Peters.1"></a>Peters S, McCallister JW. Treatment of moderate persistent asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ProAir.1">
<a name="ProAir.1"></a>ProAir Digihaler (albuterol) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ProAir.2">
<a name="ProAir.2"></a>ProAir HFA (albuterol) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ProAir.3">
<a name="ProAir.3"></a>ProAir RespiClick (albuterol) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ProAir.4">
<a name="ProAir.4"></a>ProAir RespiClick (albuterol) [prescribing information]. Horsham, PA: Teva Respiratory; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Proventil.1">
<a name="Proventil.1"></a>Proventil HFA (albuterol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17897250">
<a name="17897250"></a>Putcha N, Allon M. Management of hyperkalemia in dialysis patients. <i>Semin Dial</i>. 2007;20(5):431-439.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/17897250/pubmed" id="17897250" target="_blank">17897250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2863296">
<a name="2863296"></a>Rachelefsky GS and Siegel SC, “Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,” <i>J Allergy Clin Immunol</i>, 1985, 76(3):409-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2863296/pubmed" id="2863296" target="_blank">2863296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-709492">
<a name="709492"></a>Ray I, Evans CJ. Paranoid psychosis with Ventolin (salbutamol tablets b.p.). <i>Can Psychiatr Assoc J</i>. 1978;23(6):427. doi:10.1177/070674377802300622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/709492/pubmed" id="709492" target="_blank">709492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28291127">
<a name="28291127"></a>Regli A, Becke K, von Ungern-Sternberg BS. An update on the perioperative management of children with upper respiratory tract infections. <i>Curr Opin Anaesthesiol</i>. 2017;30(3):362-367. doi:10.1097/ACO.0000000000000460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/28291127/pubmed" id="28291127" target="_blank">28291127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30839405">
<a name="30839405"></a>Saw HP, Chiu CD, Chiu YP, Ji HR, Chen JY. Nebulized salbutamol diminish the blood glucose fluctuation in the treatment of non-oliguric hyperkalemia of premature infants. <i>J Chin Med Assoc</i>. 2019;82(1):55-59. doi:10.1016/j.jcma.2018.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/30839405/pubmed" id="30839405" target="_blank">30839405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25727842">
<a name="25727842"></a>Say B, Degirmencioglu H, Gozde Kanmaz Kutman H, Uras N, Dilmen U. Supraventricular tachycardia after nebulized salbutamol therapy in a neonate: case report [in English and Spanish]. <i>Arch Argent Pediatr</i>. 2015;113(2):e98-100. doi:10.5546/aap.2015.e98<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/25727842/pubmed" id="25727842" target="_blank">25727842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11574353">
<a name="11574353"></a>Scalfaro P, Sly PD, Sims C, Habre W. Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children. <i>Anesth Analg</i>. 2001;93(4):898-902. doi:10.1097/00000539-200110000-00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11574353/pubmed" id="11574353" target="_blank">11574353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30053954">
<a name="30053954"></a>Schissler AJ, Celli BR. Prevalence of paradoxical bronchoconstriction after inhaled albuterol. <i>Respir Med</i>. 2018;141:100-102. doi:10.1016/j.rmed.2018.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/30053954/pubmed" id="30053954" target="_blank">30053954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2927990">
<a name="2927990"></a>Schuh S, Parkin P, Rajan A, et al, “High- Versus Low-Dose, Frequently Administered, Nebulized Albuterol in Children With Severe, Acute Asthma,” <i>Pediatrics</i>, 1989, 83(4):513-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2927990/pubmed" id="2927990" target="_blank">2927990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2216613">
<a name="2216613"></a>Schuh S, Reider MJ, Canny G, et al, “Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses,” <i>Pediatrics</i>, 1990, 86(4):509-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2216613/pubmed" id="2216613" target="_blank">2216613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1513726">
<a name="1513726"></a>Schweich PJ, Hurt TL, Walkley EI, Mullen N, Archibald LF. The use of nebulized albuterol in wheezing infants. <i>Pediatr Emerg Care</i>. 1992;8(4):184-188. doi:10.1097/00006565-199208000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/1513726/pubmed" id="1513726" target="_blank">1513726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12464943">
<a name="12464943"></a>Sears MR. Adverse effects of beta-agonists. <i>J Allergy Clin Immunol</i>. 2002;110(6 Suppl):S322-8. doi:10.1067/mai.2002.129966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/12464943/pubmed" id="12464943" target="_blank">12464943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28068594">
<a name="28068594"></a>Sentilhes L, Sénat MV, Ancel PY, et al. Prevention of spontaneous preterm birth: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). <i>Eur J Obstet Gynecol Reprod Biol</i>. 2017;210:217-224. doi:10.1016/j.ejogrb.2016.12.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/28068594/pubmed" id="28068594" target="_blank">28068594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21377030">
<a name="21377030"></a>Simons FE, Ardusso LR, Bilò MB, et al; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. <i>J Allergy Clin Immunol</i>. 2011;127(3):587-93.e1-e22. doi: 10.1016/j.jaci.2011.01.038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/21377030/pubmed" id="21377030" target="_blank">21377030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12091845">
<a name="12091845"></a>Singh BS, Sadiq HF, Noguchi A, Keenan WJ. Efficacy of albuterol inhalation in treatment of hyperkalemia in premature neonates. <i>J Pediatr</i>. 2002;141(1):16-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/12091845/pubmed" id="12091845" target="_blank">12091845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8302698">
<a name="8302698"></a>Spiller HA, Ramoska EA, Henretig FM, et al, “A Two-Year Retrospective Study of Accidental Pediatric Albuterol Ingestions,” <i>Pediatr Emerg Care</i>, 1993, 9(6):338-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8302698/pubmed" id="8302698" target="_blank">8302698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174783">
<a name="16174783"></a>Spooner LM, Olin JL. Paradoxical bronchoconstriction with albuterol administered by metered-dose inhaler and nebulizer solution. <i>Ann Pharmacother</i>. 2005;39(11):1924-1927. doi:10.1345/aph.1G248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/16174783/pubmed" id="16174783" target="_blank">16174783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21682173">
<a name="21682173"></a>Stack MA, Hakemi A. Diagnosis and treatment of exercise-induced bronchospasm: a review. <i>JAAPA</i>. 2011;24(6):26-30. doi:10.1097/01720610-201106000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/21682173/pubmed" id="21682173" target="_blank">21682173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20689475">
<a name="20689475"></a>Stanojevic DA, Alla VM, Lynch JD, Hunter CB. Case of reverse takotsubo cardiomyopathy in status asthmaticus. <i>South Med J</i>. 2010;103(9):964. doi:10.1097/SMJ.0b013e3181eb349d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/20689475/pubmed" id="20689475" target="_blank">20689475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stoller.1">
<a name="Stoller.1"></a>Stoller JK. COPD exacerbations: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20552622">
<a name="20552622"></a>Tandeter H, Kobal S, Katz A. Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature. <i>Clin Cardiol</i>. 2010;33(6):E116-E120. doi:10.1002/clc.20663<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/20552622/pubmed" id="20552622" target="_blank">20552622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7893301">
<a name="7893301"></a>Udezue E, D'Souza L, Mahajan M. Hypokalemia after normal doses of neubulized albuterol (salbutamol). <i>Am J Emerg Med</i>. 1995;13(2):168-171. doi:10.1016/0735-6757(95)90086-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/7893301/pubmed" id="7893301" target="_blank">7893301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6)e239; <i>Circulation</i>. 2011;124(15):e405]. <i>Circulation.</i> 2010;122(18)(suppl 3):S829-S861. doi: 10.1161/CIRCULATIONAHA.110.971069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ventolin.1">
<a name="Ventolin.1"></a>Ventolin (albuterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ventolin.2">
<a name="Ventolin.2"></a>Ventolin Diskus (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; April 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ventolin.3">
<a name="Ventolin.3"></a>Ventolin Diskus (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ventolin.4">
<a name="Ventolin.4"></a>Ventolin HFA inhalation aerosol (salbutamol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ventolin.5">
<a name="Ventolin.5"></a>Ventolin HFA inhalation aerosol (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ventolin.6">
<a name="Ventolin.6"></a>Ventolin IV infusion solution (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline, Inc; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19694973">
<a name="19694973"></a>von Ungern-Sternberg BS, Habre W, Erb TO, Heaney M. Salbutamol premedication in children with a recent respiratory tract infection. <i>Paediatr Anaesth</i>. 2009;19(11):1064-1069. doi:10.1111/j.1460-9592.2009.03130.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/19694973/pubmed" id="19694973" target="_blank">19694973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31009034">
<a name="31009034"></a>von Ungern-Sternberg BS, Sommerfield D, Slevin L, Drake-Brockman TFE, Zhang G, Hall GL. Effect of albuterol premedication vs placebo on the occurrence of respiratory adverse events in children undergoing tonsillectomies: The REACT randomized clinical trial. <i>JAMA Pediatr</i>. 2019;173(6):527-533. doi:10.1001/jamapediatrics.2019.0788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/31009034/pubmed" id="31009034" target="_blank">31009034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27665489">
<a name="27665489"></a>Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. <i>J Allergy Clin Immunol</i>. 2016;138(5):1292-1295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/27665489/pubmed" id="27665489" target="_blank">27665489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9697678">
<a name="9697678"></a>Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. <i>J Am Soc Nephrol</i>. 1998;9(8):1535-1543.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9697678/pubmed" id="9697678" target="_blank">9697678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18936701">
<a name="18936701"></a>Weisberg LS. Management of severe hyperkalemia. <i>Crit Care Med</i>. 2008;36(12):3246-3251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/18936701/pubmed" id="18936701" target="_blank">18936701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wenzel.1">
<a name="Wenzel.1"></a>Wenzel S. Treatment of severe asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 4, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11399724">
<a name="11399724"></a>Werner HA. Status asthmaticus in children: a review. <i>Chest</i>. 2001;119(6):1913-1929. doi:10.1378/chest.119.6.1913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11399724/pubmed" id="11399724" target="_blank">11399724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2790100">
<a name="2790100"></a>Whitehouse AM, Novosel S. Salbutamol psychosis. <i>Biol Psychiatry</i>. 1989;26(6):631-633. doi:10.1016/0006-3223(89)90088-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2790100/pubmed" id="2790100" target="_blank">2790100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7937293">
<a name="7937293"></a>Wiley JF 2nd, Spiller HA, Krenzelok EP, et al, “Unintentional Albuterol Ingestion in Children,” <i>Pediatr Emerg Care</i>, 1994, 10(4):193-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/7937293/pubmed" id="7937293" target="_blank">7937293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794201">
<a name="29794201"></a>Williams DM, Rubin BK. Clinical Pharmacology of Bronchodilator Medications. <i>Respir Care</i>. 2018;63(6):641-654. doi:10.4187/respcare.06051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/29794201/pubmed" id="29794201" target="_blank">29794201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). WHO Recommendations on interventions to improve preterm birth outcomes. 2015. <a href="https://www.ncbi.nlm.nih.gov/books/NBK321160/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK321160/</a>.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13290 Version 627.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
